Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has provided unprecedented results in cancer treatment in the recent years. Development of chemical inhibitors for this pathway lags the antibody development because of insufficient structural information. The first nonpeptid...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Zak, Krzysztof M., Grudnik, Przemyslaw, Guzik, Katarzyna, Zieba, Bartosz J., Musielak, Bogdan, Dömling, Alexander, Dubin, Grzegorz, Holak, Tad A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058683/
https://ncbi.nlm.nih.gov/pubmed/27083005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8730
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky